Bergaptol, a mechanism-based inactivator of CYP2C9

被引:3
作者
Jiang, Tingting [1 ,2 ]
Cheng, Ting [1 ,2 ]
Li, Jing [1 ,2 ]
Zhou, Mengyue [1 ,2 ]
Tan, Rong [1 ,2 ]
Yang, Xiaojing [3 ]
Wang, Yang [1 ,2 ]
Li, Weiwei [1 ,2 ]
Zheng, Jiang [1 ,2 ,3 ,4 ]
机构
[1] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Guizhou Prov Key Lab Pharmaceut, Guiyang 550004, Guizhou, Peoples R China
[2] Guizhou Med Univ, Sch Pharm, Guiyang 550004, Guizhou, Peoples R China
[3] Shenyang Pharmaceut Univ, Sch Pharm, Wuya Coll Innovat, Shenyang 550025, Liaoning, Peoples R China
[4] Guizhou Med Univ, Key Lab Environm Pollut Monitoring & Dis Control, Minist Educ, Guiyang 550025, Guizhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Grapefruit; Bergaptol (BGT); Mechanism-based inactivation (MBI); Grape-drug interaction; GRAPEFRUIT JUICE; CYTOCHROME-P450; BIOSYNTHESIS; DERIVATIVES; INHIBITION; ENZYMES; 2C9;
D O I
10.1007/s00044-020-02564-x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Grapefruit-mediated fruit-drug interaction has been well discussed in clinical practice. However, the biochemical mechanisms for such interaction are far beyond our understanding. The objectives of the present study aimed at the interaction between bergaptol (BGT) and CYP2C9. BGT, one of the major furanocoumarin constituents in grapefruit, has been reported to inhibit the activity of CYP2C9. And a number of furan-containing compounds are known to act as mechanism-based inactivators of CYP2C9. In this study, BGT was found to induce time-, concentration-, and NADPH-dependent irreversible inhibition of CYP2C9. A GSH conjugate was detected in an incubation mixture containing CYP2C9, BGT, NADPH, and GSH. Further mechanistic investigation revealed that a gamma-ketoenal metabolite was responsible for the enzyme inactivation. The obtained data indicate that BGT was a mechanism-based inactivator of CYP2C9. The study would facilitate the understanding of the mechanistic insight into fruit-drug interactions mediated by grapefruits.
引用
收藏
页码:1230 / 1237
页数:8
相关论文
共 50 条
  • [31] Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9)
    Schmelzle, Moritz
    Dizdar, Levent
    Matthaei, Hanno
    Baldus, Stephan E.
    Wolters, Judith
    Lindenlauf, Nina
    Bruns, Ingmar
    Cadeddu, Ron-Patrick
    Kroepil, Feride
    Topp, Stefan A.
    Esch, Jan Schulte Am, II
    Eisenberger, Claus F.
    Knoefel, Wolfram T.
    Stoecklein, Nikolas H.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2011, 94 (1-2) : 25 - 33
  • [32] Tailoring the Specificity and Reactivity of a Mechanism-Based Inactivator of Glucocerebrosidase for Potential Therapeutic Applications
    Rempel, Brian P.
    Tropak, Michael B.
    Mahuran, Don J.
    Withers, Stephen G.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2011, 50 (44) : 10381 - 10383
  • [33] Cree antidiabetic plant extracts display mechanism-based inactivation of CYP3A4
    Tam, Teresa W.
    Liu, Rui
    Arnason, John T.
    Krantis, Anthony
    Staines, William A.
    Haddad, Pierre S.
    Foster, Brian C.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2011, 89 (01) : 13 - 23
  • [34] Engineered Bacterial Mimics of Human Drug Metabolizing Enzyme CYP2C9
    Rentmeister, Andrea
    Brown, Tristan R.
    Snow, Christopher D.
    Carbone, Martina N.
    Arnold, Frances H.
    CHEMCATCHEM, 2011, 3 (06) : 1065 - 1071
  • [35] Allele and Genotype Frequencies of CYP2C9 Within an Iranian Population (Mazandaran)
    Hashemi-Soteh, Seyed Mohammad Bagher
    Shahabi-Majd, Naghi
    Gholizadeh, Ali-Reza
    Shiran, Mohammad-Reza
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (07) : 817 - 821
  • [36] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Bae, Jung-Woo
    Kim, Ji-Hong
    Choi, Chang-Ik
    Kim, Mi-Jeong
    Kim, Hyung-Ji
    Byun, Seong-Ae
    Chang, Young-Soon
    Jang, Choon-Gon
    Park, Young-Seo
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2009, 32 (02) : 269 - 273
  • [37] The role of CYP2C9 genetic polymorphisms in the oxidative metabolism of diclofenac in vitro
    Xia, Meng-Ming
    Wang, Li
    Pan, Pei-Pei
    Wang, Hai-Yun
    Chen, Meng-Chun
    Chen, Yi
    Dai, Da-Peng
    Cai, Jian-Ping
    Hu, Guo-Xin
    PHARMAZIE, 2014, 69 (12): : 898 - 903
  • [38] Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes
    Villagra, David
    Goethe, John
    Schwartz, Harold I.
    Szarek, Bonnie
    Kocherla, Mohan
    Gorowski, Krystyna
    Windemuth, Andreas
    Ruano, Gualberto
    BIOMARKERS IN MEDICINE, 2011, 5 (04) : 427 - 438
  • [39] Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes
    Liu, Renhe
    Lyu, Xiaoxuan
    Batt, Sarah M.
    Hsu, Mei-Hui
    Harbut, Michael B.
    Vilcheze, Catherine
    Cheng, Bo
    Ajayi, Kehinde
    Yang, Baiyuan
    Yang, Yun
    Guo, Hui
    Lin, Changyou
    Gan, Fei
    Wang, Chen
    Franzblau, Scott G.
    Jacobs, William R.
    Besra, Gurdyal S.
    Johnson, Eric F.
    Petrassi, Mike
    Chatterjee, Arnab K.
    Fuetterer, Klaus
    Wang, Feng
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (42) : 13011 - 13015
  • [40] Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions
    Wang, Kai
    Gao, Qing
    Zhang, Tingting
    Rao, Jinqiu
    Ding, Liqin
    Qiu, Feng
    DRUG METABOLISM REVIEWS, 2020, 52 (02) : 235 - 257